Clinical Trial Detail

NCT ID NCT02752685
Title Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


Nab-paclitaxel + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.